|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:e-Therapeutics
Krebsforschung
Oxford Drug Design
|
|
gptkbp:awards
|
various industry awards
|
|
gptkbp:ceo
|
gptkb:Dr._Werner_Lanthaler
|
|
gptkbp:clinical_trial
|
multiple ongoing trials
|
|
gptkbp:collaborations
|
academic institutions
pharmaceutical companies
biotech companies
|
|
gptkbp:community_engagement
|
active in community engagement programs
|
|
gptkbp:employees
|
over 3,000
|
|
gptkbp:focus
|
biologics
small molecules
clinical development
preclinical development
integrated drug discovery
|
|
gptkbp:founded
|
gptkb:1993
|
|
gptkbp:global_presence
|
operates in multiple countries
|
|
gptkbp:headquarters
|
gptkb:Hamburg,_Germany
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Evotec (Germany) Gmb H
|
|
gptkbp:industry
|
gptkb:drug
|
|
gptkbp:innovation
|
focus on innovative technologies
|
|
gptkbp:invention
|
numerous patents in drug discovery
|
|
gptkbp:location
|
gptkb:Europe
gptkb:Asia
gptkb:North_America
|
|
gptkbp:partnerships
|
gptkb:Sanofi
gptkb:Boehringer_Ingelheim
gptkb:Celgene
collaborates with leading hospitals
|
|
gptkbp:publishes
|
numerous scientific publications
|
|
gptkbp:research_areas
|
oncology
rare diseases
neuroscience
cardiovascular diseases
infectious diseases
immunology
metabolic diseases
|
|
gptkbp:revenue
|
€300 million (2020)
|
|
gptkbp:services
|
drug discovery
development services
|
|
gptkbp:stock_exchange
|
gptkb:Frankfurt_Stock_Exchange
|
|
gptkbp:subsidiary
|
gptkb:Evotec_SE
|
|
gptkbp:sustainability
|
commitment to sustainability practices
|
|
gptkbp:symbol
|
EVT
|
|
gptkbp:website
|
www.evotec.com
|
|
gptkbp:bfsParent
|
gptkb:Evotec_AG
gptkb:Evotec
|
|
gptkbp:bfsLayer
|
3
|